The guidance outlines how the IVDR transitional provisions relate to expert panels and EURLs. Effective October 1, 2024, EURLs will be fully operational and will undertake specific responsibilities as detailed in Articles 10-16 of Commission Implementing Regulation (EU) 2022/944. Devices certified under the IVDR prior to the activation of the EURLs will maintain valid certification until their specified expiry dates. However, sample or batch testing will be required for all certified devices falling under the EURLs’ scope. In these instances, Notified Bodies are obligated to coordinate with the EURLs to meet the requirements set forth in Articles 10, 11, and 13 of the Commission Implementing Regulation.
What does it mean to you?
MDCG 2021-4 Revision 1 is relevant to all manufacturers of Class D IVDs, as it may clarify questions regarding the operational procedures of the EURLs.
About the Author
MSc Biomedical Sciences · Director Authorised Representative Services & Manager IVD – Regulatory Affairs
With over 20 years of experience in the diagnostics industry, Kirsten leads the IVD Regulatory Affairs business unit at QbD Group, guiding regulatory strategy and compliance across all IVDs with a focus on companion diagnostics.
Related Resources
EU GMP: How to import your products into the EU?
Are you a medicinal product manufacturer looking to import your products into the EU in line with the latest EU-GMP impo
Medical Device Regulation (MDR) Checklist
Implement the Medical Device Regulation (MDR) with ease. Download our checklist of mandatory documents for MDR complianc
A Decade of Excellence: Linguistic Review Support for a Global Pharma Leader
QbD Group streamlines linguistic reviews for a leading pharma client, ensuring compliance and accuracy across 25 EU/EEA
Subscribe to the latest updates in life science
Expert perspectives delivered to your inbox — pick your interests.
No spam, ever. Unsubscribe anytime.
